According to a new study, people who are genetically more likely to have cardiovascular diseases can benefit from boosting a biomarker found in fish oils.
In a genetic study of 1,886 Asian Indians published today (Wednesday, May 12, 2021) in PLOS ONE, scientists have the first evidence of the role of adiponectin, an obesity-related biomarker, in the context of a genetic variation called Omentin and Identifies Cardiometabolic Health.
The team, led by Professor Vimal Karani of the University of Reading, found that the role of adiponectin was related to markers of cardiovascular disease that were independent of common and central obesity in the Asian Indian population.
Prof. Vimal Karani, Professor of Nutrigenetics and Nutrigenomics at the University of Reading, said:
“This is an important finding about how people who are not overweight can develop heart disease from having low levels of a biomarker in their body called adiponectin. It can also show why certain lifestyle factors like eating fatty fish and getting regular exercise are so important in staving off the risk of heart disease.
“We studied Asian Indian populations at particular genetic risk for developing heart disease and found that the majority of our participants were already cardiometabolically unhealthy. However, the genetic variation of omentin we studied is widespread across different ethnic groups and requires further research to determine whether omentin plays a role in heart disease risk in other groups as well. “
In the Asian Indian population participating in the study, a significant association was found between low adiponectin levels and cardiovascular disease, even after adjusting for factors normally associated with heart disease.
Study participants were screened and rated using a range of cardiovascular measures such as BMI, fasting blood sugar, and cholesterol. More than 80% of the participants were classified as cardiometabolically unhealthy.
Further analysis showed that those with genetic variation in omentin production also had fewer biomarkers of adiponectin in their bodies.
Professor Vimal Karani said:
“It is clear from the observations that there is a three-step process in which the difference in the omentin gene contributes to the low biomarker adiponectin, which in turn appears to be linked to poorer outcomes and risk of heart disease.
“The omentin gene itself produces a protein in the body that has been shown to have anti-inflammatory and cardioprotective effects, and variations in the omentin gene have previously been linked to cardiometabolic disorders. The results suggest that because of this specific omentin genetic risk, people may develop cardiometabolic disease when they have low levels of the biomarker adiponectin. “
Reference: May 12, 2021, PLOS ONE.
DOI: 10.1371 / journal.pone.0238555
Funding: The Chennai Willingdon Corporate Foundation supported the CURES field studies.